John Krauss is an Oncology physician affiliated with University of Michigan. OpenAlex indexes 195 publications with 9,146 citations (h-index 40).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 E Medical Center Dr
Ann Arbor, MI 481095000
Telephone
734-936-4000Registry record last updated 1 Oct 2019.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20251 payment
- Janssen Research & Development, LLCProgram year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
23.5%Serotonin-3 Receptor Antagonist7%Ondansetron Hcl100%Part D≥26 patientsProton pump inhibitor5.9%Omeprazole100%Part D≥12 patients+ 2 more classes in this area
Cardiovascular
13.3%Antiarrhythmic5.4%Lidocaine-Prilocaine100%Part D≥15 patientsCalcium channel blocker2.9%Amlodipine Besylate100%Part D<11 patients+ 2 more classes in this area
Cancer & immunology
13.3%Aromatase Inhibitor4.5%Anastrozole100%Part D<11 patientsNucleoside Analog Antiviral3.2%Lonsurf100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 1991–1994 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy
Journal of Clinical Oncology
2022 - Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2.
Journal of Clinical Oncology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Moshe Talpaz, MD
University of Michigan
William Herman, MD
University of Michigan
Max Wicha, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”